Welcome to the online home of the Chris M. Carlos and Catherine Nicole Jockisch Carlos Endowment for Primary Sclerosing Cholangitis (PSC). Thanks to support provided by this endowment, dedicated Mayo Clinic investigators and their teams are making strides to better understand and treat PSC patients, with the ultimate goal of developing a cure for this disease.
Follow the PSC page and stay up-to-date as we post news about advances in PSC research, clinical trials, and available resources.
Recently, we have made the decision to include periodically in our PSC blog commentaries of selected clinical studies published by other groups. This tactic aims at keeping the followers of this blog informed about current efforts of the academic community at large to better understand and treat PSC.
In this month’s issue of the Scandinavian Journal of Gastroenterology John E. Eaton et al., reports on the results of a 12-week open-label pilot study to examine whether curcumin, a naturally occurring compound, could reduce the markers of cholestasis in patients with PSC. Curcumin is the principal curcuminoid of [...]
In a review published in Nature Reviews Gastroenterology and Hepatology this month (see below), Jesus Banales et al., provides an excellent and comprehensive overview of cholangiocyte pathobiology as relates to the development of biliary diseases like PSC. Initially, the authors emphasize on the normal function of cholangiocytes, [...]
Cell free DNA (cfDNA) are degraded DNA fragments released to the blood stream during health and disease. This discovery was made more than 50 years ago. However, it was not until recently with the advent, scalability and affordability of next generation sequencing that cfDNA has become an approach to study biomarkers for disease [...]
In an abstract presented this week at the 2019 European Association for the Study of the Liver (EASL) meeting in Vienna, Austria, Dr. John Eaton from Mayo Clinic, Rochester, MN, reported the confirmation of the PREsTo machine learning algorithm for the prognostication of disease progression in a randomized trial [...]